Volume 19, Number 7—July 2013
Rifampin-Resistant Mycobacterium bovis BCG–Induced Disease in HIV-Infected Infant, Vietnam
To the Editor: Guidelines for the diagnosis and management of Mycobacterium bovis BCG disease in HIV-infected children are lacking. BCG strains are intrinsically resistant to pyrazinamide and in some cases have low-level resistance to isoniazid (6). However, data on acquired drug resistance in M. bovis BCG are limited. We describe a case of BCG disease caused by a rifampin-resistant strain of M. bovis BCG in an HIV-infected infant in Vietnam.
The daughter of a known HIV-infected woman, who did not fully adhere to antiretroviral therapy (ART) during pregnancy, received the M. bovis intradermal BCG (Pasteur strain) vaccine at birth. HIV infection was diagnosed in the infant by PCR when she was 8 weeks of age. At 9 months of age, she was admitted to the Pediatric Infectious Diseases Department of the Pham Ngoc Thach Hospital (Ho Chi Minh City, Vietnam) because of a voluminous ipsilateral axillary mass at the site of the vaccination, fever, weight loss, and hepatosplenomegaly. The percentage of CD4+ T cells was 27% (1,620 cells/mm3). Regional BCG disease was clinically diagnosed without microbiological investigation, and a broad antimycobacterial therapy targeting M. tuberculosis complex species was started with 5 mg/kg isoniazid, 10 mg/kg rifampin, and 25 mg/kg pyrazinamide. After 6 weeks of antimycobacterial therapy, ART was initiated with lamivudine, stavudine, and abacavir.
After 6 months of antimycobacterial treatment, the infant was hospitalized again for recurrent inflammation and fistulization of the axillary lymph nodes associated with fever. Fluid from the axillary mass was collected by fine-needle aspiration for bacteriologic investigations. Direct microscopic examination showed acid-fast bacilli, and the mycobacterial infection was confirmed by culture. By using conventional biochemical methods, the mycobacterial isolate was assigned to the M. bovis species. Pyrazinamide was discontinued, and antimycobacterial therapy was continued for 4 supplementary months with rifampin (15 mg/kg) and isoniazid (10 mg/kg). After 2 months, drug susceptibility testing results confirmed pyrazinamide intrinsic resistance and isoniazid and ethambutol susceptibility and showed rifampin resistance. The late inflammatory reaction after introduction of ART was evocative of immune reconstitution inflammatory syndrome. Nevertheless, drug resistance may have contributed. Despite the rifampin resistance, the patient showed clinical improvement, and the rifampin/isoniazid treatment was continued for 2 more months. The child’s BCG disease was cured on completion of 10 months of antituberculous treatment.
Retrospective molecular investigations using the GenoType MTBC Kit (Hain Lifescience, Nehren, Germany) enabled identification of the isolate stored at −80°C as M. bovis BCG strain. A mutation in the rpoB gene (codon 531, Ser531Tyr) associated with rifampin resistance was detected by using the GenoType MTBDRplus Kit (Hain Lifescience) and partial sequencing of the rpoB gene (5,7). No mutation in the katG and inhA genes, frequently associated with isoniazid resistance, was detected.
To our knowledge, this case is the second report of rifampin-resistant M. bovis BCG disease in HIV-infected children. The first report involved a child in South Africa who was vaccinated with the Danish BCG strain (4); this strain shows low-level resistance to isoniazid and therefore has a high risk of evolving to multidrug resistance in instances of suboptimal isoniazid levels. The M. bovis BCG Pasteur strain (American Type Culture Collection 35734) used for vaccination in Vietnam is isoniazid and rifampin susceptible and pyrazinamide resistant (9). Despite appropriate antimycobacterial treatment, the relatively low doses of isoniazid (5 mg/kg), poor adherence, or inadequate absorption of drugs because of HIV-related gastrointestinal disease may have resulted in subtherapeutic in vivo drug concentrations and thus in selection of a drug-resistant M. bovis BCG strain. This case should alert clinicians of the possible emergence of rifampin resistant M. bovis BCG strains.
Because disseminated BCG disease in HIV-infected children presents a high risk for illness and/or death, these patients should receive optimal tuberculosis treatment (2) based on 4-drug (rifampin, isoniazid, ethambutol, and pyrazinamide) regimen doses for at least 9 months until M. tuberculosis is ruled out (3). Untreated local BCG immune reconstitution inflammatory syndrome may not necessarily progress to dissemination; therefore, treatment would not appear necessary (8).
Some studies suggest that the survival of HIV-infected children with BCG disease could be attributed to early initiation of ART in combination with other treatments (1,3). In the South Africa case, the child died, and the authors suggested that this outcome was related to the severity of the clinical features, the severe HIV-related immune suppression, and the absence of ART (4). In the case in Vietnam, despite the emergence of drug resistance, the early initiation of ART in a child with a localized disease, the persistent efficacy of isoniazid, and the spontaneous fistulization of the abscess probably contributed to the good outcome for the infant.
In conclusion, this case highlights the challenges in management of BCG disease in children. It also emphasizes the possible risk for emergence of acquired drug resistance in M. bovis BCG strains, complicating the medical management of such cases.
We are grateful to all the health care teams of Pham Ngoc Thach Hospital for their help in this study. We acknowledge Didier Laureillard for the fruitful discussions.
The Institut National de la Santé et de la Recherche Médicale; Institut de Recherche pour le Développement; Centre National de la Recherche Scientifique; and Pham Ngoc Thach Hospital, particularly the Reference Laboratory for Tuberculosis, provided financial and technical support. This study was developed in the framework of the Centre National de la Recherche Scientifique–Groupements de Recherche Internationau project entitled “Biodiversity and Infectious Diseases in Vietnam.”
- Azzopardi P, Bennett CM, Graham SM, Duke T. Bacille Calmette-Guerin vaccine–related disease in HIV-infected children: a systematic review. Int J Tuberc Lung Dis. 2009;13:1331–44 .
- Hesseling AC, Caldwell J, Cotton MF, Eley BS, Jaspan HB, Jennings K, BCG vaccination in South African HIV-exposed infants—risks and benefits. S Afr Med J. 2009;99:88–91 .
- Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, Bacille Calmette-Guerin vaccine–induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42:548–58 .
- Hesseling AC, Schaaf HS, Hanekom WA, Beyers N, Cotton MF, Gie RP, Danish bacille Calmette-Guerin vaccine–induced disease in human immunodeficiency virus–infected children. Clin Infect Dis. 2003;37:1226–33 .
- Mironova S, Pimkina E, Kontsevaya I, Nikolayevskyy V, Balabanova Y, Skenders G, Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study. Eur J Clin Microbiol Infect Dis. 2012;31:1381–7 .
- Ritz N, Tebruegge M, Connell TG, Sievers A, Robins-Browne R, Curtis N. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother. 2009;53:316–8 .
- Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341:647–50 .
- Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–44 .
- Wayne LG. Microbiology of tubercle bacilli. Am Rev Respir Dis. 1982;125:31–41 .
Suggested citation for this article: Nguyen Hong D, Huyen MNT, Lan NTN, Duong NH, Nguyen Ngo VV, Ngoc DT, et al. Rifampin-resistant Mycobacterium bovis BCG–induced disease in HIV-infected infant, Vietnam. Emerg Infect Dis [Internet]. 2013 Jul [date cited]. http://dx.doi.org/10.3201/eid1907.130025
Please use the form below to submit correspondence to the authors or contact them at the following address:
Sylvain Godreuil, Centre Hospitalo–Universitaire, Hôpital Arnaude Villeneuve—Laboratoire de Bactériologie, 371 Avenue du Doyen Gaston Giraud, Montpellier cedex 5 34295, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: June 04, 2013
- Page last updated: June 04, 2013
- Page last reviewed: June 04, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)